1.Systematic Review on the Efficacy and Safety of Erenumab for the Prevention of Migraine
Pyoungwoo SON ; Hyunwoo CHAE ; Eunhee JI ; Bong Kyu YOO
Korean Journal of Clinical Pharmacy 2019;29(2):71-78
OBJECTIVE: This study aimed to provide efficacy and safety information on the use of erenumab for prevention of episodic and chronic migraines. METHODS: The keywords “Erenumab and migraine” were used to search the PubMed database to then compile efficacy and safety data for erenumab. Data from relevant Phase 2 and Phase 3 clinical trials were analyzed, using RevMan for statistical analysis. RESULTS: Three clinical trials (one Phase 2 and two Phase 3 studies) were retrieved. All three trials used the same primary endpoint (change from baseline in monthly migraine days (CBMD)) to evaluate efficacy and safety of erenumab use for prevention of episodic and chronic migraines. Subcutaneous doses of erenumab (70 or 140 mg) were administered monthly in each trial, for 3 months (Studies 2, and 3) or 6 months (Study 1). The mean differences in CBMD in the 70 mg and 140 mg erenumab arms were −1.36 and −1.98, respectively, compared to that in the placebo arm. Some adverse events, such as nasopharyngitis and upper respiratory tract infection, were reported, but no differences in safety between erenumab and placebo were found to be significant. CONCLUSIONS: Erenumab showed superior efficacy in prevention of migraines compared to placebo. However, additional information regarding the long-term safety of erenumab should be collected. Therefore, post-marketing surveillance for adverse events is needed.
Arm
;
Migraine Disorders
;
Nasopharyngitis
;
Respiratory Tract Infections
2.Bleeding after Taking Dual Antiplatelets and NSAID Concurrently.
Jeongmin SEO ; Joonghyuk CHOI ; Pyoungwoo SON ; Seungmin LEE ; Hyunwoo CHAE ; Geunhyung KANG ; Eunhee JI
Korean Journal of Clinical Pharmacy 2018;28(3):250-253
When stenting is applied to treat myocardial infarction, antiplatelet agents are administered to prevent thrombosis, which increases the risk of bleeding. Patients with myocardial infarction are also more likely to have osteoarthritis simultaneously, because both diseases occur frequently in elderly patients. Patients with osteoarthritis often use analgesics, especially nonsteroidal anti-inflammatory drugs (NSAIDs); hence, patients with both diseases use analgesics and antiplatelet agents simultaneously. The risk of bleeding increases with the use of antiplatelet agents and this is further increased when NSAIDs are added. We would like to report a case that reflects this situation. A 60-year-old man underwent stenting after ST-elevation myocardial infarction, and was treated with aspirin and clopidogrel. This patient also received a pelubiprofen prescription from another physician to treat osteoarthritis. After the patient took pelubiprofen twice, he found a bruise on his wrist and reported it to the pharmacist. It is unlikely that this is rare in community pharmacies, so pharmacists should pay careful attention to the concomitant administration of analgesics to patients receiving antiplatelet agents and should provide appropriate education to patients.
Aged
;
Analgesics
;
Anti-Inflammatory Agents, Non-Steroidal
;
Aspirin
;
Contusions
;
Education
;
Hemorrhage*
;
Humans
;
Middle Aged
;
Myocardial Infarction
;
Osteoarthritis
;
Pharmacies
;
Pharmacists
;
Platelet Aggregation Inhibitors
;
Prescriptions
;
Stents
;
Thrombosis
;
Wrist
3.Psychiatric Symptoms after Taking Oseltamivir in a Child and Its Causality Assessment
Pyoungwoo SON ; Joonghyuk CHOI ; Seungmin LEE ; Seon Soon PARK ; Eunkyung CHOI ; Bong Kyu YOO ; Eunhee JI
Korean Journal of Clinical Pharmacy 2019;29(1):56-60
Oseltamivir is an antiviral medication prescribed to prevent and treat influenza A and B. A case from a community pharmacy in Korea was reported for an adverse event associated with oseltamivir administration. A 20-month-old boy had psychiatric symptoms after receiving 2 doses of oseltamivir. Therefore, an evaluation of whether the psychiatric symptoms were caused by oseltamivir was required. To determine whether the adverse event resulted from the administrated medication or other factors, three tools were used: the Naranjo scale, the Korean causality assessment algorithm (Ver.2), and the World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria. The psychiatric symptoms occurred after oseltamivir administration, and were attenuated after oseltamivir termination. A possible cause of the psychiatric symptoms is high fever, but information on the body temperature of the patient was not sufficient. Therefore, it was unclear whether there were other nonpharmacological causes of adverse drug reaction. For these reasons, in terms of causality, the results evaluated by the three tools represented, “possible”, “probable”, and “probable/likely”, respectively.
Body Temperature
;
Child
;
Drug-Related Side Effects and Adverse Reactions
;
Fever
;
Global Health
;
Humans
;
Infant
;
Influenza, Human
;
Korea
;
Male
;
Oseltamivir
;
Pharmacies